Atorvastatin use also reduces HSC activation via the production of sterol regulatory element-binding protein 1 (SREBP1) and peroxisomal proliferator-activated receptor (PPAR) (Marinho et al., 2017), in addition to the reduction in fibrosis and portal hypertension via non-canonical Hedgehog signaling (Uschner et al., 2015). Here, SREBF1 is linked to liver disorder.